☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - May 2021

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Indacaterol / glycopyrronium / mometasone inhaler (Enerzair Breezhaler®) has been accepted for use as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Indacaterol / mometasone inhaler (Atectura Breezhaler®) has been accepted for use as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short-acting beta2-agonists.

Glycopyrronium / formoterol inhaler (Bevespi Aerosphere®) has been rejected for use as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease. The manufacturer failed to make a submission for this indication.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - May 2021' on Email Share 'SMC Update - May 2021' on Delicious Share 'SMC Update - May 2021' on Digg Share 'SMC Update - May 2021' on Facebook Share 'SMC Update - May 2021' on reddit Share 'SMC Update - May 2021' on Twitter

atomic-wealth

No Comments to “SMC Update - May 2021”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.

vipers